Exact Sciences licenses colon cancer biomarkers; Pacific Biomarkers puts its menu online;

> Exact Sciences has licensed two DNA methylation biomarkers that can be used to test for colon cancer. Story

> Seattle-based Pacific Biomarkers is putting its menu of biomarkers online. The company, which markets biomarket lab services, has put up PacBio.com for buyers to peruse its offerings both by disease type or simply alphabetically. Release

> Axela has bought out Xceed Molecular, which gives it control over the Ziplex gene-expression analysis platform and assays. Story

> Amar Sethi, VP of science and technology at Pacific Biomarkers, is the lead author of a research study published in the July issue of the journal Clinical Chemistry. The study identifies the potential use of two diagnostic markers for ischemic heart disease. Release

And Finally... A new report says that men who are at low risk for aggressive prostate cancer often are provided the most aggressive treatments anyway following a PSA test. Report

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.